PMID- 16934010
OWN - NLM
STAT- MEDLINE
DCOM- 20070116
LR  - 20191110
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 21
IP  - 7
DP  - 2006 Jul
TI  - Pharmacotherapy implications of revised chronic heart failure guidelines.
PG  - 576-82
AB  - OBJECTIVE: To provide an overview of major drug therapy recommendations within 
      recently revised chronic heart failure (CHF)guidelines. DATA SOURCES: Guideline 
      statements and English-language articles from MEDLINE pertinent to CHF. STUDY 
      SELECTION AND DATA EXTRACTION: Recently published guidelines from the American 
      College of Cardiology (ACC)/American Heart Association (AHA) and the Heart 
      Failure Society of America (HFSA) served as the focus of this review. Prospective 
      comparative trials, review articles, and editorials were also considered. DATA 
      SYNTHESIS: Recommendations within the ACC/AHA and HFSA guidelines continue to 
      provide a systematic, evidence-based approach regarding CHF management. The HFSA 
      guidelines recommend that the severity of clinical disease and functional 
      limitation be characterized using the New York Heart association (NYHA) 
      functional classification system. A key feature of the ACC/AHA guidelines is the 
      use of a staging system that recognizes the development and progression of heart 
      failure. Both guidelines stress the importance of neurohormonal blockade with 
      angiotensin-converting enzyme inhibitors and beta-adrenergic blockers. Moreover, 
      the guidelines expand the role of aldosterone antagonists, angiotensin II 
      receptor blockers, and hydralazine/isosorbide dinitrate, particularly in 
      combination with standard treatments. Diuretics and digoxin remain symptomatic 
      treatments only. CONCLUSIONS: This article summarizes key drug therapy 
      recommendations from the revised ACC/AHA and HFSA guideline statements. 
      Pharmacists caring for CHF patients should be familiar with these recommendations 
      and aid in their implementation.
FAU - Crouch, Michael A
AU  - Crouch MA
AD  - Virginia Commonwealth University, Richmond, VA 23298-0533, USA. macrouch@vcu.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant 
      Pharmacists
JID - 9013983
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 26NAK24LS8 (Hydralazine)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angiotensin II Type 1 Receptor Blockers/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Chronic Disease
MH  - Clinical Trials as Topic
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Hydralazine/therapeutic use
MH  - Practice Guidelines as Topic/*standards
MH  - Societies, Medical/organization & administration/standards
RF  - 28
EDAT- 2006/08/29 09:00
MHDA- 2007/01/17 09:00
CRDT- 2006/08/29 09:00
PHST- 2006/08/29 09:00 [pubmed]
PHST- 2007/01/17 09:00 [medline]
PHST- 2006/08/29 09:00 [entrez]
AID - 10.4140/tcp.n.2006.576 [doi]
PST - ppublish
SO  - Consult Pharm. 2006 Jul;21(7):576-82. doi: 10.4140/tcp.n.2006.576.